In recent years, the incidence of gynecological tumors has increased year by year, making the terms cervical cancer and ovarian cancer no longer unfamiliar to us. Cervical cancer is the most common gynecological malignant tumor. In addition, it is also the three major gynecological malignant tumors along with ovarian cancer and endometrial cancer. Gynecological similitudinem anorum are harmful to women. Early detection and early diagnosis can often help treatment and improve the survival time of patients.
Celeri cursus iaculis justo ac immunotherapy condicionem aegrorum gynecologicorum cancer valde emendavit. Editor inspice probatum tumorem gynecologicum iaculis justo pharmaca et immunotherapye medicamenta tibi.
Lorem cancer Gynecologic targeted
ovarian cancer Lorem targeted
②PARP Matrix
Olaparib (Olapani, Lynparza), rucaparib (Rucapa, Rubraca) et niraparib (Nilapani, Zejula)
Lorem ceruicis cancer medicinae targeted
Bevacizumab (Bevacizumab, avastin)
Lorem endometrial cancer targeted
Hormone vel consequat purus hormones usus verti arcu. Remedia includit:
Progesterone diam: et medroxyprogesterone acetate megestrol acetate
diam Tamoxifen
Luteinizing hormone-diam Hormon agonists: Goserelin (Norred®) et Leuprolide (Leuprolide®). Haec medicamentacito infusum omnis 1-3 mensibus
Aromatase diam inhibitors: letrozole (Fronon®), anastrozole (Reninide®), exemestane (Anoxin®)
Tuba SARCOMA Lorem targeted
Diam Panzopinab (Votrient) est Lorem potest targeted ad propagationem et facies leiomyosarcoma quae relapsus post curatio.
Ø Olaratumab (Lartruvo) compositum cum medicamento chemotherapy doxorubicino ad sarcoma mollis textus tractandum. Adhiberi potest sarcoma uterina tractare quae aliis curationibus non respondet.
Gynecological tumore immunotherapy
Immunotherapy is a relatively new concept, not widely used like surgery, chemotherapy and radiotherapy. However, it has made great progress in improving the survival of patients with advanced lung cancer, melanoma, kidney cancer, Lymphoma Hodgkin scriptor and so on. Only one drug is approved for gynecological tumor immunotherapy! But for two different situations, the star drug is pembrolizumab (Pembrolizumab, Keytruda).
Pembrolizumab (Keytruda) scuta PD-1, quae interdum in cellulis T et plerumque adiuvat, ne has cellas alias cellulas in corpore aggrediatur. Obstruendo PD-1, haec medicamenta responsionem immunem cellis cancri augere possunt, ut tumores aliquos augere vel retardare possint.
MSI DVD-H Gynecologic Oncology
Die 24 Maii 2017, US FDA approbavit inhibitorem pembrolizumab PD-I (Pembrolizumab, Keytruda) ut aegros cum microsatellite valde instabili (MSI-H) / mismatch defectus reparandi mismatch (dMMR) typicus tumores XV varias tumores malignos tractare possidet cancer iecoris, cancer colorectalis, cancer pulmonis et cancer cervicalis, cum variis tumoribus gynecologicis. (Nota: si MSI-H detegatur, nihil refert utrum mane sit an sero, prodesse possis)
PD-L1 positivum ceruicis cancer
In June hoc anno, in US FDA approbatione est accelerated pembrolizumab (Keytruda) est PD-L1-positivum curatio provectus ex morbo processus in ceruicis cancer aegris quorum nec cum chemotherapy. Probat quod definit in PD-L1 positivum ceruicis cancer combined per a positivum score (CPS) Transierunt ≥1 quod FDA approbavit test results. Est dignum quod, ut nunc, Keytruda primus et solus probatus est etiam anti-PD-I est Lorem provectus ceruicis cancer.
Et datum est immunotherapy medicamento intravenous a singulis, et hebdomades III (IV) infusionem causet. In Sinis est currently enumerantur intrat et medicinae assecurationis. Domesticis possunt aegris hospitium loci ad consultandum accersunt, aut Global vocant oncologist Network (3-400-626) view details mark pembrolizumab curatio de ceruicis cancer.
Et approbatione notitia fundatur in aegris cum XCVIII ex portu vel in metastatic ceruicis cancer Phase II iudicium INCENTIVUS, CLVIII. Haec global, aperta, non temere-, multa et studio multicenter aestimari multiple genera pembrolizumab in curatio de cum aegris tumores provectus solidum, et ex his aegris fecerunt progressus vexillum treatment protocols.
11.7 tunc sequitur mediana Menses (0.6-22.7 rhoncus). In totalis efficax rate (Orr) PD-L77 positive in aegris LXXVII (CPS ≥ I) 1% erat. Hi omnes erant aegris metastatic aegris cum morbo, qui accepit de ≥ I recta chemotherapy. Orr, et quod habet completum responsionem rate of 1% participationem rate of 14.3% responsio. Mediana responsio tempus est non pervenit (range ad 1 menses mensibus + 2.6), et responsionem XCI% of conventi erat tempus VI menses vel longior.
Nam cum aegris PD-L1 expressio CPS <I, nullus fuit responsum retulit.
'Quamquam illic fuerunt plurimi procedentes sequatur gynecological cancer, ante tractata patientibus proficiebat ceruicis cancer adhuc mihi deest novum treatment options' inquit Bradley, monachus, et Arizona oncologist, medicinae director de American Gynecology Research oncology Program et doctor in obstetrics and gynecology. In denuntiatione,
"Keytruda de hac approbatione amet indication est et nuntium-oncologist quod est a ipsum excitando ad arbitrium pro his aegris opus," addidit, monachus.
In patientibus curatio responsio LXXVII histological gradus erant, XCII% Plattenepithelkarzinom, ADENOCARCINOMA VI%,% I adenosquamous et carcinomate. XCV% de aegris habere metastases, et XX% sunt relapsi sunt. 77C92 IHC in PD-L6 pharmDx ornamentum solebat determinare est status in PD-L1.
Omnis XXIV menses III septimanas ad adventum pembrolizumab aegroti accepit CC mg forma vel sponte cessit curatio, aut confirmatio radiological progressum in morbo, seu inquisitor unacceptable toxicity, aut secundum consilium est. Amet firmum cum aegris radiological progressum curatio potet continire ad profectum confirmata est, ex imagine a subsequent. Tumor omnis IX hebdomades progressus aestimari quod in primo anno et postmodum omnis XII weeks.
De maxime communis (≥10% de aegris) adversa nuntiavit certe (AES) includitur laborem in omnibus gradibus (XLIII%) dolor (XXII%), febrem (XIX%), periphericis OEDEMA (XV%), et dolore musculoskeletal (XXVII %)), deiectio / colitis (XXIII%), dolor abdominis (XXII%) nauseam (XIX%), vomitus (XIX%), constipation (XIV%), minuatur appetitus (XXI%), sanguinem (XIX%), uti (XVIII%) infectio (XVI%) temeraria (XVII%), hypothyroidism (XI%), capitis (XI%) et DYSPNOEA (X%).
De maxime commune aes gradus includit uti 3/4 (VI%), sanguinem (V%) musculoskeletal dolor (V%), Labor (V%) infectio (6%), dolor abdominis (5%) dolor (II )%) periphericorum hydropicus (II%) temeraria (II%), capitis (II%), deiectio / colitis (II%), saniem eructans (I%), DYSPNOEA (I%) et febricitantem (I%)).
Curatio se discontinuandi de AE ad occurrit, in VIII% de aegris. In gravibus aes occurrit XXXIX% de aegris, maxime commune anemia (VII%) fistula (8%), sanguinem (39%), et infectio (nisi uti, 7%).
Approbatio tumoris gynecologici immunotherapy proculdubio unam paleam salutaris vitae addet, unam optionem curationum, et plus spei superstes aegros qui chemotherapy, hormona therapia et iaculis justo resistunt. Ex superioribus videmus tuberculum gynecologicum immunotherapy non omnibus aegris idoneum. Priusquam curationem adhibeant, duo tentandi tumorem figunt: unus est MSI, alter PD-L1. Aegris qui signa conveniunt magis idoneus est.
Etsi pembrolizumab in Sinis iam venales sunt, nonnulli aegros sentiant pretium huius pharmaci relative carum esse. Si vis servare sumptus geneticae probationis, temere probas pembrolizumab. Haec ratio quoque non mala est, sed fere, si id non est, pembrolizumab ipsa curatione aliqua parte effectus et in curatione aliquos effectus negativos habere.
Si potest non praestatur beneficium, non potest Esse, et de conditione afficit.
For cancer friends whose survival period is not optimistic, the doctor ‘s estimate may be less than 6 months, and the economic conditions are not good. In this case, if you take half a month to wait for an uncertain result, it seems too risky, so It is better to conduct a blind test directly, use the money on the blade, and select the most probable one to try, commonly known as “Chuangyun”.
Scilicet, caecus experimentum etiam suum delictum habet. Ante experimentum geneticum non est, medicamentum basically a "suspicio" pendet, et effectus fundamentaliter fretus est "orare".
